APRE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Aprea Therapeutics Inc (APRE) is not a strong buy at this time for a beginner investor with a long-term focus. The stock is experiencing significant downward price pressure, lacks positive financial growth trends, and has no immediate catalysts to drive a rebound. While insider buying is a positive signal, the company's financials and technical indicators suggest caution. A hold strategy is recommended until clearer growth signals emerge.
The MACD histogram is positive but contracting, indicating weakening momentum. RSI is neutral at 48.002, suggesting no clear overbought or oversold conditions. Moving averages are converging, showing no strong trend direction. The stock is trading below its pivot level of 0.927, with key support at 0.78 and resistance at 1.075.
Insiders are buying, with a 147.37% increase in buying activity over the last month.
The stock has experienced significant dilution due to recent financing through pre-funded warrants. Financial performance is weak, with a 98.38% YoY revenue drop and negative net income. Analysts have consistently lowered price targets, citing dilution and weak financials.
In Q4 2025, revenue dropped by 98.38% YoY to 3337. Net income fell by 15.17% YoY to -2,455,630. EPS decreased by 34.69% YoY to -0.32. Gross margin remained flat at 100%. Overall, financial performance is poor, with no signs of recovery.
Analysts maintain a Buy rating but have significantly lowered price targets due to dilution concerns. H.C. Wainwright reduced the target to $1.20 from $4, and Wedbush reduced it to $7 from $11. Analysts acknowledge some clinical progress but remain cautious due to financial and dilution issues.
